Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3542456 | 0.83 | OPRL1 (0.46) | PTGDR2NR1H4SLC6A9HTR2A | |
| SCHEMBL3543822 | 0.70 | OPRL1 (0.56) | NR1H4HTR2A | |
| SCHEMBL5037801 | 0.66 | TACR1 (0.45) | NR1H4HTR2A | |
| SCHEMBL25609126 | 0.65 | HTR2A (0.46) | NR1H4HTR2A | |
| SCHEMBL13207042 | 0.65 | PIK3CD (0.40) | NR1H4 | |
| SCHEMBL18928463 | 0.64 | PIK3CD (0.44) | EZH2 | |
| SCHEMBL14838596 | 0.64 | NR1H4 (0.41) | NR1H4EZH2HTR2A | |
| SCHEMBL16992109 | 0.64 | CHEK1 (0.45) | NR1H4HTR2A | |
| SCHEMBL13250230 | 0.63 | HSD11B1 (0.43) | NR1H4EZH2HTR2A | |
| SCHEMBL4973584 | 0.63 | PIK3CD (0.43) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829586-B2 | Aryl-substituted nitrogen-containing heterocyclic compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| US-20090275617-A1 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds | MSD K.K. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1935881-A1 | ARYL-SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275617-A1 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds | OPRL1, NPSR1, NPBWR1 | PTGDR2 333/4885NR1H4 355/4885EZH2 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.